JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients
| Autor: | Emanuela Ottaviani, Mauro Fiacchini, Federica Salmi, Francesca Palandri, Michele Baccarani, Giovanni Martinelli, Lucia Catani, Nicola Polverelli, Nicola Vianelli |
|---|---|
| Přispěvatelé: | Palandri F, Ottaviani E, Salmi F, Catani L, Polverelli N, Fiacchini M, Martinelli G, Baccarani M, Vianelli N. |
| Rok vydání: | 2009 |
| Předmět: |
JAK2 V617F MUTATION
Adult Male Cancer Research medicine.medical_specialty Pathology Time Factors Essential thrombocythemia JAK2 V617F mutation Long-term outcome Time Factor Adolescent Antineoplastic Agents Gastroenterology Follow-Up Studie Antineoplastic Agent Cohort Studies hemic and lymphatic diseases Internal medicine ESSENTIAL THROMBOCYTHEMIA medicine Biomarkers Tumor Humans Platelet Aged Aged 80 and over business.industry Incidence (epidemiology) Valine Hematology Janus Kinase 2 Middle Aged medicine.disease Thrombosis Treatment Outcome Oncology Mutation (genetic algorithm) Cohort Mutation Female Hemoglobin Cohort Studie business Human Cohort study Follow-Up Studies Thrombocythemia Essential |
| Zdroj: | Leukemialymphoma. 50(2) |
| ISSN: | 1029-2403 |
| Popis: | The JAK2(V617F) mutation occurs in 50% of patients with essential thrombocythemia (ET). We investigated the correlation between the JAK2(V617F) mutation and clinical and laboratory characteristics, thrombohemorrhagic risk and incidence of disease evolution in 275 patients with ET followed for a median follow-up of 7 years. JAK2(V617F) mutation was detected in 175 patients (64%), of whom 173 were heterozygous. Patients with the mutation were older and displayed higher hemoglobin and hematocrit levels, but lower platelet count. Cytotoxic treatment requirement was similar in the two groups, but patients with the mutation showed better responses. Incidence of thrombosis and disease evolution was comparable. JAK2 mutational status assessment was valuable to distinguish two populations of patients with ET, showing distinctive hematologic and clinical features. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|